JP2015506376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506376A5 JP2015506376A5 JP2014555805A JP2014555805A JP2015506376A5 JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5 JP 2014555805 A JP2014555805 A JP 2014555805A JP 2014555805 A JP2014555805 A JP 2014555805A JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- patient
- cancer
- administering
- cdk8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 10
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 8
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 150000003384 small molecules Chemical class 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims 4
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102100024170 Cyclin-C Human genes 0.000 claims 3
- 239000012623 DNA damaging agent Substances 0.000 claims 3
- 101000980770 Homo sapiens Cyclin-C Proteins 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- YQGHJCYLMLPCCB-UHFFFAOYSA-N 2,4-diaminopyrimidin-5-ol Chemical compound NC1=NC=C(O)C(N)=N1 YQGHJCYLMLPCCB-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- -1 small molecule compound Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010064390 Tumour invasion Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000009400 cancer invasion Effects 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594023P | 2012-02-02 | 2012-02-02 | |
| US61/594,023 | 2012-02-02 | ||
| US201261673419P | 2012-07-19 | 2012-07-19 | |
| US61/673,419 | 2012-07-19 | ||
| PCT/US2013/024515 WO2013116786A1 (en) | 2012-02-02 | 2013-02-01 | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506376A JP2015506376A (ja) | 2015-03-02 |
| JP2015506376A5 true JP2015506376A5 (enExample) | 2016-05-19 |
| JP6193268B2 JP6193268B2 (ja) | 2017-09-06 |
Family
ID=47716178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555805A Expired - Fee Related JP6193268B2 (ja) | 2012-02-02 | 2013-02-01 | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9321737B2 (enExample) |
| EP (2) | EP2809324B1 (enExample) |
| JP (1) | JP6193268B2 (enExample) |
| KR (1) | KR20150023223A (enExample) |
| CN (1) | CN104363913B (enExample) |
| AU (1) | AU2013214783B2 (enExample) |
| BR (1) | BR112014019052A8 (enExample) |
| CL (1) | CL2014002062A1 (enExample) |
| CO (1) | CO7151516A2 (enExample) |
| EA (2) | EA028595B1 (enExample) |
| GE (2) | GEP20186818B (enExample) |
| MY (1) | MY165446A (enExample) |
| PH (1) | PH12014501862A1 (enExample) |
| SG (1) | SG11201404596UA (enExample) |
| UA (1) | UA117342C2 (enExample) |
| WO (1) | WO2013116786A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6324380B2 (ja) | 2012-07-27 | 2018-05-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物 |
| RU2015107550A (ru) * | 2012-08-23 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Новые фенилпиридин/пиразинамиды для лечения рака |
| KR20160014568A (ko) | 2012-11-01 | 2016-02-11 | 유니버시티 오브 싸우스 캐롤라이나 | 전립선암을 치료하는 방법 |
| WO2014134169A1 (en) * | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| JP6529085B2 (ja) * | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2016018511A2 (en) * | 2014-06-10 | 2016-02-04 | University Of South Carolina | Methods and compositions for treatment of her-positive cancers |
| US20210322651A1 (en) | 2014-12-18 | 2021-10-21 | Senex Biotechnology, Inc. | Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| RU2017142394A (ru) * | 2015-05-08 | 2019-06-10 | Президент Энд Феллоус Оф Гарвард Колледж | Целевой отбор пациентов для лечения производными кортистатина |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| AU2016348659B2 (en) | 2015-11-03 | 2022-07-28 | Apriligen, Inc. | Compounds for treatment of hypoproliferative disorders |
| WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
| JP7198489B2 (ja) * | 2016-03-23 | 2023-01-04 | 国立大学法人 岡山大学 | リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用 |
| US11285144B2 (en) | 2016-08-03 | 2022-03-29 | The Broad Institute, Inc. | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity |
| CN114921468A (zh) * | 2017-01-30 | 2022-08-19 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| WO2018151633A1 (ru) * | 2017-02-20 | 2018-08-23 | Закрытое Акционерное Общество "Биокад" | Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов |
| WO2018156858A1 (en) * | 2017-02-23 | 2018-08-30 | University Of South Carolina | Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis |
| EP3591040A4 (en) * | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS |
| RU2641001C1 (ru) * | 2017-04-03 | 2018-01-15 | Закрытое Акционерное Общество "Биокад" | Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция |
| AU2018249154A1 (en) * | 2017-04-03 | 2019-11-21 | Kyoto Pharmaceutical Industries, Ltd. | Novel cyclin-dependent kinase 8 and/or 19 inhibitor |
| JP7392954B2 (ja) * | 2017-09-18 | 2023-12-06 | シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー | トリプルネガティブ乳癌の治療方法 |
| WO2019068613A1 (en) | 2017-10-02 | 2019-04-11 | Boehringer Ingelheim International Gmbh | NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS |
| RU2763347C2 (ru) * | 2018-03-01 | 2021-12-28 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| US12281080B2 (en) | 2018-08-21 | 2025-04-22 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| CN113677341B (zh) | 2019-02-01 | 2024-07-05 | 南卡罗莱纳大学 | 双环吡啶组合物及其用于癌症治疗的方法 |
| JP7805009B2 (ja) | 2020-11-20 | 2026-01-23 | オリヅルセラピューティクス株式会社 | 成熟化剤 |
| TW202246489A (zh) | 2021-02-09 | 2022-12-01 | 日商千紙鶴治療公司 | 成熟化劑 |
| EP4313050A4 (en) * | 2021-03-25 | 2025-02-12 | University of South Carolina | CDK8/19 INHIBITORS FOR CYTOKINIC STORM TREATMENT |
| AU2022349176A1 (en) | 2021-09-27 | 2024-04-11 | Kyoto University | Method for producing t cell |
| US20250018033A1 (en) | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| MX2024006370A (es) | 2021-11-24 | 2024-08-19 | Regcell Co Ltd | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. |
| CN119256076A (zh) | 2022-03-23 | 2025-01-03 | 国立大学法人京都大学 | 用于产生调节性t细胞的方法 |
| AU2023262842A1 (en) | 2022-04-25 | 2024-09-12 | Orizuru Therapeutics, Inc. | Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity |
| WO2024014497A1 (ja) | 2022-07-14 | 2024-01-18 | オリヅルセラピューティクス株式会社 | 細胞移植用のフィブリンゲルシート |
| EP4596684A1 (en) | 2022-09-26 | 2025-08-06 | Regcell Co., Ltd. | Induced regulatory t cells containing chimeric antigen receptor (car) |
| EP4600352A1 (en) | 2022-09-26 | 2025-08-13 | Kyoto University | T cell production method |
| KR20250140618A (ko) | 2023-02-08 | 2025-09-25 | 레그셀 가부시키가이샤 | 천포창을 치료 또는 예방하기 위한 의약 조성물 |
| JPWO2024204553A1 (enExample) | 2023-03-29 | 2024-10-03 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| PL342447A1 (en) * | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
| US20040180844A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| US20040180848A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| BRPI0409241A (pt) * | 2003-04-10 | 2006-03-28 | Pfizer | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso |
| US20080033000A1 (en) * | 2006-05-15 | 2008-02-07 | Senex Biotechnology, Inc. | Identification of CDKI pathway inhibitors |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
-
2013
- 2013-02-01 KR KR1020147024672A patent/KR20150023223A/ko not_active Ceased
- 2013-02-01 BR BR112014019052A patent/BR112014019052A8/pt not_active Application Discontinuation
- 2013-02-01 EP EP13704538.1A patent/EP2809324B1/en not_active Not-in-force
- 2013-02-01 AU AU2013214783A patent/AU2013214783B2/en not_active Ceased
- 2013-02-01 UA UAA201409643A patent/UA117342C2/uk unknown
- 2013-02-01 JP JP2014555805A patent/JP6193268B2/ja not_active Expired - Fee Related
- 2013-02-01 GE GEAP201714080A patent/GEP20186818B/en unknown
- 2013-02-01 SG SG11201404596UA patent/SG11201404596UA/en unknown
- 2013-02-01 US US13/757,682 patent/US9321737B2/en active Active
- 2013-02-01 WO PCT/US2013/024515 patent/WO2013116786A1/en not_active Ceased
- 2013-02-01 CN CN201380017703.9A patent/CN104363913B/zh not_active Expired - Fee Related
- 2013-02-01 EP EP18186536.1A patent/EP3431087A1/en not_active Withdrawn
- 2013-02-01 EA EA201491399A patent/EA028595B1/ru not_active IP Right Cessation
- 2013-02-01 EA EA201791284A patent/EA032429B1/ru not_active IP Right Cessation
- 2013-02-01 GE GEAP201313566A patent/GEP201706688B/en unknown
- 2013-02-01 MY MYPI2014002269A patent/MY165446A/en unknown
-
2014
- 2014-08-01 CL CL2014002062A patent/CL2014002062A1/es unknown
- 2014-08-18 PH PH12014501862A patent/PH12014501862A1/en unknown
- 2014-08-30 CO CO14191136A patent/CO7151516A2/es unknown
-
2016
- 2016-03-09 US US15/065,083 patent/US10993945B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506376A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016501221A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| RU2017105353A (ru) | Соединения | |
| JP2010525056A5 (enExample) | ||
| RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| EA201500293A1 (ru) | Антихолинэргическая нейропротективная композиция и способы | |
| JP2016522254A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2019505529A5 (enExample) | ||
| RU2014139955A (ru) | Прокаспазная комбинированная терапия при глиобластоме | |
| JP2015522018A5 (enExample) | ||
| EP3720560A1 (en) | Methods of treating cancer with plk4 inhibitors | |
| JP2011046708A5 (enExample) | ||
| RU2015101702A (ru) | Фармацевтически активные соединения | |
| EA201270298A1 (ru) | Способ лечения злокачественной опухоли |